CN103800308B - 环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 - Google Patents
环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 Download PDFInfo
- Publication number
- CN103800308B CN103800308B CN201310385753.4A CN201310385753A CN103800308B CN 103800308 B CN103800308 B CN 103800308B CN 201310385753 A CN201310385753 A CN 201310385753A CN 103800308 B CN103800308 B CN 103800308B
- Authority
- CN
- China
- Prior art keywords
- carcinoma
- triterpene
- preparing
- antitumor drug
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BSLYZLYLUUIFGZ-JRUDBKCSSA-N 4,4,14-trimethyl-9,19-cyclo-5alpha,9beta-cholestane Chemical compound C1CCC(C)(C)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 BSLYZLYLUUIFGZ-JRUDBKCSSA-N 0.000 title claims abstract description 11
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 title claims abstract description 11
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 150000003648 triterpenes Chemical class 0.000 title claims abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 8
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 8
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims abstract description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims abstract description 7
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 5
- 201000001514 prostate carcinoma Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 230000001472 cytotoxic effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 241000345998 Calamus manan Species 0.000 abstract description 5
- 241000758724 Schisandraceae Species 0.000 abstract description 4
- 235000012950 rattan cane Nutrition 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 125000001033 ether group Chemical group 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 241000165690 Solanum wightii Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- 241000561698 Schisandra pubescens Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- -1 triterpenoid compound Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NJFOSFIPGRXARF-QYLNPOJUSA-N Nigranoic acid Chemical compound C1C[C@@H](C(C)=C)[C@@]2(CCC(O)=O)C[C@@]32CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C(O)=O)C)CC[C@@]2(C)[C@@H]31 NJFOSFIPGRXARF-QYLNPOJUSA-N 0.000 description 1
- NJFOSFIPGRXARF-UHFFFAOYSA-N Nigranoin-saeure Natural products C1CC(C(C)=C)C2(CCC(O)=O)CC32CCC2(C)C(C(CCC=C(C)C(O)=O)C)CCC2(C)C31 NJFOSFIPGRXARF-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000736075 Schisandra Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002258 gallium Chemical class 0.000 description 1
- 150000002291 germanium compounds Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000002596 lutein cell Anatomy 0.000 description 1
- SOWPPACPMKVOEL-UHFFFAOYSA-N manwuweizic acid Natural products OC(=O)CCC1(C)C(C(C)=C)CCC2=C1CCC1(C)C(C(CCC=C(C)C(O)=O)C)CCC12C SOWPPACPMKVOEL-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- TXNBIFNTDYSZNF-UHFFFAOYSA-N nigranoic acid Natural products CC(CCC=C(C)/C(=O)O)C1CCC2(C)C3CCC(C4(C)CC4)C5(CCC(=O)O)CC35CCC12C TXNBIFNTDYSZNF-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属中药制药领域，涉及一种环菠萝蜜烷型降三萜在制备抗肿瘤药物中的新用途。本发明从五味子科毛叶五味子（S.pubescens）藤茎的乙醚部位分离得到micranoic？acid？B，体外抗肿瘤活性筛选试验证实，该化合物对人肺癌（A549）、前列腺癌（PC-3）、鼻咽癌（KB）和鼻咽癌耐药株（KBvin）均具有显著的细胞毒活性，GI50分别达到4.40μg/mL、4.07μg/mL、4.34μg/mL及4.10μg/mL。
Description
技术领域
本发明属中药制药领域，涉及一种环菠萝蜜烷型降三萜在制备抗肿瘤药物中的新用途。
背景技术
在多种疾病中，癌症一直是威胁人类生命最可怕的疾病之一.据世界卫生组织(WH0)统计资料表明，全世界癌症每年发病约1000万人，死亡约700万人，已成为仅次于心血管病的人类第二号杀手。因此，寻找有效的抗癌药物已成为当务之急.在抗癌药物研究中，化疗药物的研究和临床应用已取得很大进展。化学合成的抗癌药如金属配合物铂络合物、鎵盐、有机锗化合物、锡配合物等具有抗癌性强、抗瘤广谱等特点，但也存在毒副作用大、造价高、水溶性差等不足之处。所以研究者们将目光投向资源丰富、纯天然的中草药。近几年来,从中草药中寻找新的抗癌药物已被证明是个很有前途的方向，天然抗癌药物的筛选自然就成了现今的一个研究热点。目前已有研究表明天然产物包括中草药中的紫杉醇、喜树碱、长春新碱、鬼臼毒素等具有很好的抗癌活性并在临床上得到广泛的应用。
五味子科（Schisandraceae）植物在民间广泛作为药用。近代化学成分及药理活性研究表明，三萜类化合物是本科植物的主要活性成分之一，具有抗HIV和抗肿瘤等药理作用。如从合蕊五味子中分离得到的三萜酸nigranoicacid和漫五酸（manwuweizicacid）体外对人蜕膜细胞及大鼠黄体细胞具有很强的细胞毒活性，从长梗五味子中分离得到的longipedlactoneA-C体外对A549、HT-29和K562具有明显的细胞毒活性。
毛叶五味子Schisandrapubescens为五味子科五味子属植物，产于甘肃、湖北、四川、云南及西藏等地，文献中对其化学成分及药理作用研究较少。化合物micranoicacidB是从该植物藤茎中分离得到的一种环菠萝蜜烷型降三萜，结构上为已知化合物，但未见对其抗肿瘤活性方面的报道。
发明内容
本发明的目的是提供一种已知化合物环菠萝蜜烷型降三萜在制备抗肿瘤药物中的新用途。
本发明应用现代药理筛选方法，对植物药中抗肿瘤活性物质进行研究，从五味子科毛叶五味子（S.pubescens）藤茎的乙醚部位分离得到化合物micranoicacidB并证实其有显著的抗肿瘤活性。
本发明涉及的环菠萝蜜烷型降三萜化合物micranoicacidB具有式I的化学结构：
本发明所述的环菠萝蜜烷型降三萜通过下述方法制备：
毛叶五味子藤茎粗粉室温下以95％乙醇反复冷浸、渗漉提取数次后，减压回收溶剂，得到的浸膏悬浮于蒸馏水中，以乙醚萃取。取乙醚萃取物上硅胶柱，依次以石油醚、石油醚-乙酸乙酯、乙酸乙酯进行梯度洗脱。洗脱流份再经反复硅胶柱色谱进行分离，得到化合物micranoicacidB。
该化合物经体外SRB法抗肿瘤活性筛选试验，结果证实所述化合物对人肺癌A549、前列腺癌PC-3、鼻咽癌KB和鼻咽癌耐药株KBvin四种肿瘤细胞株均具有明显的细胞毒活性，GI50分别为4.40μg/mL、4.07μg/mL、4.34μg/mL及4.10μg/mL。表明micranoicacidB具有抗肿瘤药用价值。
本发明实验采用的试剂、细胞株均为本领域公知技术，可市购。
本发明的环菠萝蜜烷型降三萜化合物可制备抗肿瘤药物。所述的肿瘤包括肺癌、前列腺癌和鼻咽癌。
附图说明：
图1是毛叶五味子中micranoicacidB的提取分离流程图。
具体实施方式
实施例1制备micranoicacidB
毛叶五味子藤茎粗粉10kg室温下以95％乙醇反复冷浸、渗漉提取5次，减压回收溶剂，浸膏加2L水混悬，以乙醚萃取4次（每次2L）。取乙醚萃取物190g经浓缩、硅胶拌样、烘干后，以湿法装硅胶柱，干法上样，依次以石油醚、石油醚-乙酸乙酯、乙酸乙酯进行梯度洗脱。石油醚-乙酸乙酯（8∶2）洗脱所得的流份进行硅胶柱色谱，再经石油醚-乙酸乙酯（10∶1～3∶1）梯度洗脱，其中石油醚-乙酸乙酯（4∶1）洗脱流份经反复硅胶柱色谱后，得到micranoicacidB（10mg），其化学结构经波谱分析并与文献（Chemical&PharmaceuticalBulletin,2003,51:1174）数据对照后鉴定。
实施例2体外抗肿瘤试验（SRB法）
A549、PC-3、KB和KBvin四种肿瘤细胞株在含25mM的HEPES、0.2%(w/v)碳酸氢钠和100μg/ml卡那霉素的10％小牛血清RPMI1640培养液4ml的T-25烧瓶中，37℃，5%CO2的条件下培养。经胰蛋白酶消化后的细胞悬浮液加入96孔板中，细胞浓度为0.25-1×104/孔。肿瘤细胞加入不同浓度的待测组分在37℃培养72小时后，用冰冷的50%三氯乙酸固定并用0.4%的(SRB)染色，待染料溶解后，562nm下测定吸收值。细胞半数生长抑制时的药物浓度GI50按照量效数据进行换算。每个实验重复三次，吸收值差异小于5%，GI50差异小于30%。以GI50≤20μg/ml为有效标准。结果如表1所示，micranoicacidB对肺癌细胞、前列腺癌细胞、鼻咽癌细胞及其耐药株都有明显的细胞毒活性；GI50分别为4.40μg/mL、4.07μg/mL、4.34μg/mL及4.10μg/mL。
表1是micranoicacidB的细胞毒活性（GI50inμg/ml）。
表1
*：阳性对照。
Claims (2)
1.如下结构式的环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途，
所述的环菠萝蜜烷型降三萜为micranoicacidB。
2.按权利要求1的用途，其特征在于，所述的肿瘤为肺癌、前列腺癌或鼻咽癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310385753.4A CN103800308B (zh) | 2012-11-08 | 2013-08-29 | 环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210445940.2 | 2012-11-08 | ||
| CN2012104459402 | 2012-11-08 | ||
| CN201210445940 | 2012-11-08 | ||
| CN201310385753.4A CN103800308B (zh) | 2012-11-08 | 2013-08-29 | 环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103800308A CN103800308A (zh) | 2014-05-21 |
| CN103800308B true CN103800308B (zh) | 2016-03-30 |
Family
ID=50698012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310385753.4A Expired - Fee Related CN103800308B (zh) | 2012-11-08 | 2013-08-29 | 环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103800308B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115057770B (zh) * | 2022-06-09 | 2023-06-13 | 湖南农业大学 | 黑老虎果皮中三萜酸化合物的制备方法 |
-
2013
- 2013-08-29 CN CN201310385753.4A patent/CN103800308B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 两种五味子科药用植物活性成分的研究,许利嘉, 中国优秀博硕士学位论文全文数据库 (博士) 医药卫生科技辑,2006年第12期;许利嘉;《中国优秀博硕士学位论文全文数据库 (博士) 医药卫生科技辑》;20061215(第12期);44-46 * |
| 北五味子三萜类化合物分离纯化、结构鉴定及抗肝癌活性研究,李斌，中国博士学位论文全文数据库 医药卫生科技辑，2012年第6期;李斌;《中国博士学位论文全文数据库 医药卫生科技辑》;20120615(第6期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103800308A (zh) | 2014-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parveen et al. | Phytochemicals targeting VEGF and VEGF-related multifactors as anticancer therapy | |
| CN104415070A (zh) | 一种人参中人参总皂苷的分离纯化方法 | |
| CN104341430A (zh) | 一种土甘草a及其提取方法和用途 | |
| CN104586945A (zh) | 啤酒花总黄酮提取物、制备方法及其作为制备预防和治疗肝损伤、癌症药物的应用 | |
| CN104311623B (zh) | 一种名为油茶皂苷c1和油茶皂苷c2的五环三萜类化合物及其制备方法与应用 | |
| CN103800308B (zh) | 环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 | |
| CN104490894A (zh) | 阔叶丰花草三萜化合物的制备方法及其在制备糖苷酶抑制剂药物中的应用 | |
| CN103610682B (zh) | 3α-羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
| CN102100692B (zh) | 异戊烯基二氢黄酮类化合物在制备抗肿瘤药物中的用途 | |
| CN101747190A (zh) | 没药烷型倍半萜类化合物及其制备方法和应用 | |
| CN104523792A (zh) | 一种富含强心苷的马利筋乳汁提取物及其制备方法与应用 | |
| CN106554340B (zh) | 一种紫藤瘤中单体化合物的用途及其分离纯化方法 | |
| CN103800319B (zh) | 4-芳基四氢萘型木脂素在制备抗肿瘤药物中的用途 | |
| CN105418722B (zh) | 一种名为油茶皂苷c4和c5的五环三萜类化合物的制备方法 | |
| CN105837506B (zh) | 毛序准噶尔乌头中二萜类生物碱的制备方法和用途 | |
| CN105801634B (zh) | 核桃青皮中一种直链醇苷化合物的制备方法和应用 | |
| CN105001188B (zh) | 一种艾里莫芬烷型倍半萜二聚体及其制备方法和应用 | |
| CN104274429B (zh) | 环阿尔廷型三萜化合物在制备抗肺癌药物中的应用 | |
| CN105412083B (zh) | 异虎耳草素的应用 | |
| CN105330713B (zh) | 3β‑乙酰氧基人参皂苷F1及其提取方法和药物用途 | |
| CN105820044B (zh) | 一种新型c22二萜化合物及其制备方法和应用 | |
| CN104529968B (zh) | 一种抗肿瘤二萜类化合物，其药物组合物及其制备方法和用途 | |
| CN103694302B (zh) | 2α,3β-二羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
| CN101361749B (zh) | 甾体皂苷类化合物及其在制备抗肿瘤药物中的用途 | |
| CN103923075A (zh) | 新型链状二萜类化合物的制备与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |